Testing for STIs was carried out at baseline and every 12 weeks thereafter for up to 2 years. Cervico-vaginal samples were collected by trained study doctors and tested at the research centre laboratory. Samples were tested for Trichomonas vaginalis (OSOM Trichomonas Test, Sekisui Diagnostics LLC, USA), Chlamydia trachomatis and Neisseria gonorrhoea (Cobas Amplicor CT/NG PCR test, Roche Diagnostic Systems, Branchburg, New Jersey, USA). Those who tested positive for STIs were treated following the Uganda national guidelines for syndromic management of STIs24 and the Centers for Disease Control and Prevention (CDC) treatment guidelines for aetiological diagnoses.25 (link)
Osom trichomonas test
Manufactured by Sekisui
Sourced in United States
The OSOM® Trichomonas Test is a rapid, qualitative immunoassay designed for the detection of Trichomonas vaginalis antigen in female vaginal/endocervical swab specimens. The test provides a visual result, indicating the presence or absence of the Trichomonas vaginalis antigen.
Automatically generated - may contain errors
3 protocols using osom trichomonas test
1
STI Screening and Management in Uganda
2
HIV, Trichomoniasis, and Syphilis Testing
3
STI Screening and HIV Testing Protocol
Check if the same lab product or an alternative is used in the 5 most similar protocols
+ Expand
Creatinine clearance was estimated based on serum creatinine measurements using the Cockroft Gault equation. Testing for Neisseria gonorrhoeae (GC) and Chlamydia trachomatis (CT) was by nucleic acid amplification (GeneXpert®, Cepheid, Sunnyvale, CA), and Trichomonas vaginalis (TV) by rapid test (OSOM® Trichomonas Test, Sekisui Diagnostics, Burlington MA). HIV status was determined by a point of care fourth‐generation rapid HIV test (Determine Abbott, Abbott Park, IL USA) followed by the Trinity Unigold test, and if either was reactive, an instrumented fourth‐generation antigen/antibody immunoassay (Architect Abbott Combo®, Abbott Laboratories). If the fourth‐generation instrumented test was positive, RNA testing was performed to differentiate acute infection from a false‐positive antigen/antibody test.
For drug level feedback, intracellular TFV‐DP levels in DBS were measured at the University of Cape Town Division of Clinical Pharmacology Laboratory, which developed and validated an indirect method for the quantification of tenofovir diphosphate in 50 µL human DBS, in collaboration with the University of Colorado Pharmacology laboratory, which developed the assay and determined thresholds with directly observed dosing [28 ].
For drug level feedback, intracellular TFV‐DP levels in DBS were measured at the University of Cape Town Division of Clinical Pharmacology Laboratory, which developed and validated an indirect method for the quantification of tenofovir diphosphate in 50 µL human DBS, in collaboration with the University of Colorado Pharmacology laboratory, which developed the assay and determined thresholds with directly observed dosing [
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!